Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$20m is nothing. I've seen clinical-stage companies with an accumulated deficit of $150m. You really need to study the sector. Oncolix isn't doing anything out of the ordinary. It's the cost of researching and developing drugs. Every single company in the sector that is successful has gone through it. $20m is fractions compared to an FDA approved drug on the market with billion dollar revenue potential.
We know that BioVectra is the contract manufacturer. It's even listed on the Oncolix website. It's also been confirmed by the CEO. Not sure why you're so caught up on a filing? A filing isn't necessary as this isn't considered a significant materiel event.
Oncolix has already tested Prolanta on 3 patients which is also known as the first cohort. That has been confirmed and is not required to be updated on the clinical trial page. Results on that page are not to be updated until all cohorts of phase I have been completed and the results have been audited and peer reviewed. It has already been confirmed many many times that BioVectra is the contract manufacturer for Prolanta. And no it doesn't need to appear in an 8-K as that is not considered materially significant information. The PR stating that the drug was being shipped to the trial site from the contract manufacturer is enough to suffice.
36 days or less to get this second cohort kicked off, but could literally start any day at this point.
Facts
You do realize that the original filings at the time of the merger listed Greenville Health System as the investor with the physical address being the hospital's. The investor name had to be changed to Health Sciences Center since they bought out GHS and became the new owners. You will need to take it up with the Health Sciences Center for why they provided that address, but it's not incorrect. And Oncolix didn't ask HSC to take over, but there really isn't anything they can do about it. They have always done business with GHS.
Health Sciences Center LLC
33 East McBee Avenue, Suite 400, Greenville, South Carolina 29601 Is not the address they filed with the state with?
This looks like even more Evidence? It just keeps compiling?
He makes a good point. The stock is so thinly traded that you could barely get any shares between .04-.05 right now. Any aggressive buying pressure would force the PPS up to .07-.08 immediately. Until that happens, it's best to accumulate when they ask is right and also sit on the bid. Without a catalyst, that strategy is the best way to get shares at the moment.
This looks like more evidence?
That's true that it may never be released, but the odds are in our favor that it will.
I don't see why the Asian licensing partner wouldn't happen? Prolanta has serious potential given the science and research supporting it. Why wouldn't another company want a piece of a potential breakthrough cancer treatment?
OW*P ran from .002 to $3.23 from positive IRB approval and safety data for a medical marijuana cream for psoriasis. Market cap was damn near $500m. Innovation Pharmaceuticals ran from .15 up to $4.93 from positive phase I data with a market cap approaching $1B during that run. And I don't think Oncolix is just going to put out a PR that says phase I had no adverse effects. It's going to note efficacy if there is any, which it should given what we know about the last cohort. This will also be at an escalated dose too, meaning even more efficacy.
IMO
They have enough money to get through the first part of phase I. If that yields solid results, the PPS should increase at least to the .30-.50 range. That will be enough for them to get more funding without hurting investor value. They will also get non toxic funding from a foreign licensing partner. And like I've said before, since this is an orphan drug, if the results are significant after phase II, they can push for an FDA approval and completely forego phase III. You also have to remember that positive results, if they are significant enough, make a small company such as Oncolix an attractive buyout target. Then it won't matter if we get volume, a buyout is the best thing that can happen.
IMO
I'm holding until we get trial results. If the results are positive, that kind of news does not go unnoticed and it will spread like wildfire.
That's not really that Interesting? All three of those share counts are really really low? Oncolix? Shareholders are really really lucky?
That still doesn't prove anything? Sorry?
IMO
There's no proof that 33 East McBee Ave isn't correct? But go ahead and make something out of nothing? Wouldn't expect anything less?
IMO
I don't care if their address is on mars? if they invested money, they invested money? Their address doesn't affect the investment?
IMO
Damn you beat me to it! The bafoonery is EXTRAORDINARY!
You can't ask for better DD on an OTC stock.
IMO
Lots and lots of evidence on this board dating back to Spring/Summer.
IMO
We are 5-6 weeks max from the second cohort being dosed. But we could literally get that news any day. We know Prolanta made it to the trial site in January. Any patients that have been recruited need to wait at least 30 days for them to start treatment due to the fact that any treatments they were previously on need to be completely cleared from the body.
I think I saw someone posted that the drug had arrived to the trial site on January 10th. If they had patients recruited that week or the week after, they would have that 30 day wait already covered. So I'm thinking it's very possible we get the dosing news this week or next week.
IMO
Nope just a random passerby who felt it necessary to chime in on something they know nothing about.
I was thinking they would wait to raise the A/S into the billions until after FDA approval and Nasdaq uplisting.
IT'S_BEEN_FILED_AWAY_AS_EVIDENCE_IN_THE_UP COMING_COURT_CASE!!!
ROTFLMFAO
IMO
It's not outrageous, it's the TRUTH, which is something that some here have an absolute struggle with. I also know for a fact that that email/letter contained a bit more than just asking if Wen Chen still worked for Oncolix.
Also, Wen Chen doesn't need to be apart of the company in order to reap the benefits of a multibillion dollar FDA approved drug. It's called royalty income from pharmaceutical drug patent licensing.
IMO
Don't kid yourself, no one ever said Wen Chen is still involved with the company. For now, he would rather not be apart of the company due to certain investors harassing him. But, at the end of the day, Prolanta is still his invention, so therefore, Wen Chen will always be associated with Oncolix.
Yeah but they used the word 'erroneously', so it has to mean something LOLOLOLOLOL
Wen Chen asked to be taken off the website because of a particular investor (who is under investigation) harassing them. No matter how you slice it, his invention is and always will be Prolanta. Wen Chen is a great scientist who has created another great drug. Whether he's an advisor or not makes not one bit of difference in the success of Prolanta FYI.
Not sure what point you're trying to make about the Texas Treasury Safekeeping Trust Company. Is it because they used the word 'erroneously'? LOL so stupid. TTSTC is 100% an investor in Oncolix, are you u see the impression that they aren't?
You know the funny thing about pharmas? They all seem to get sued at one point or another. I googled 6 different Nasdaq pharmaceutical companies and all 6 were involved in lawsuits. I guess maybe we should all warn the investors of these companies to stay away as they are all clearly scams. So far Oncolix has not been in a lawsuit and the ones that involved past companies of current board members and management have all been dismissed. Things are looking bright for Oncolix!
Novartis
https://www.statnews.com/pharmalot/2016/10/05/novartis-35-million-improper-marketing/
Amgen
https://mobile.nytimes.com/2012/12/19/business/amgen-agrees-to-pay-762-million-in-drug-case.html?referer=http://www.google.com/
Pfizer
http://abcnews.go.com/Business/story?id=6062389
Valeant
https://www.forbes.com/sites/antoinegara/2017/12/30/bill-ackman-and-valeant-settle-allergan-insider-trading-lawsuit-for-290-million/
Eisai
https://www.thepharmaletter.com/article/eisai-to-settle-41-million-price-fixing-lawsuit
Abbott Laboratories
http://www.chicagotribune.com/business/ct-abbott-opioid-lawsuit-0423-biz-20170421-story.html
Celgene
https://www.fiercepharma.com/marketing/celgene-settles-for-280-million-off-label-cancer-marketing-case
I still don't see the point of posting cases that were dismissed and the men were exonerated and found innocent. Unless of course you're trying to build a positive argument in defense of these men. Also, pharma's live and die by their pipeline. Oncolix' pipeline with Prolanta is very promising. Its very simple, if Prolanta works, there's nothing any of these men can do to prevent Oncolix from being successful. It's all about Prolanta and nothing else at this point.
More slanderous material or what we now call "evidence"...
IMO
It's actually very possible.
IMO
It's not impossible and it is a very real thing that happens with companies who have orphan drug status from time to time. They already have overwhelming evidence that there are no dose limiting toxicities or adverse effects. If they escalate the dose in phase II and get high levels of efficacy with no side effects, Oncolix can receive an FDA approval as it wouldn't make sense to go into phase III if they've already proven they have an effective and safe treatment. Getting the drug to those in need would become the priority.
And it's not bad to dream about this or want this to happen. I know you are rooting against this, but if it were to happen, it would help a lot of people. Isn't that so upsetting? Imagine if Oncolix could save ovarian cancer patients? That's like the worst thing that can happen, isn't it?
Speaking of no bid, certain peoples bank accounts might end up at no bid as a result of these actions.
I'm not sure if people are aware of this, but it is POSSIBLE for Prolanta to receive an FDA approval after completing only 2 phases. This is due to its orphan drug status. Oncolix could have a drug to market sooner than we think.
http://www.curonz.com/orphan_drug.htm
BioVectra is the manufacturer and Prolanta has been safely shipped to the trial site.
12.5m shares is a rather miniscule amount to be honest and isn't something anyone here is worried about.
This is such a stupid argument. Why even ask where the money is going to come from? Everyone here knows that a pre-revenue company needs to sell shares in order to obtain capital to pay for its business operations. The key here, and everyone knows this, is for positive trial data leading to an increase in PPS. The higher the PPS, the less shares that are needed to be sold, resulting in better value for the shareholders of Oncolix. It's really simple stuff.
Imagine if Redman worked the past 10 years for free? He would be panhandling and living in a homeless shelter until Oncolix started generating revenue. Not really sure he would be fit to be a CEO if that were the case. Imagine how many successful biopharma's on the Nasdaq wouldn't have made it to where they are now if they didn't pay their employees while they were pre-revenue? Redman isn't forced to be the CEO of Oncolix and with his track record and experience, would be more than qualified to be the CEO of another biopharma getting paid a much larger salary. If you want your company run properly you need to have the right leadership. Whether your company is generating revenue or not, that leadership comes at a cost and there's no way around it. I don't think you could get another CEO to work for less than 300k, at least not one with Redmans experience and resume.